semaglutide cardiovascular trial Recent study at UC Irvine found that medication may benefit 93 million U.S. adults The SELECT Trial - A

Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al

While every patient responds differently, both semaglutide and tirzepatide represent important advancements in prescription weight loss injections

Conversely, stages of a womans life, such as adolescence, perimenopause and menopause, that are associated with reduced estradiol, are also associated with weight gain

Key warning signs requiring urgent evaluation include: Postmenopausal bleeding (any vaginal bleeding occurring more than 12 months after the last menstrual period) Bleeding accompanied by fever, unusual vaginal discharge, or pelvic pain suggesting infection Bleeding associated with pregnancy or suspected pregnancy Recurrent spotting that persists for more than two to three menstrual cycles Patients taking tirzepatide who develop abnormal bleeding should undergo a comprehensive gynecological assessment, including detailed menstrual history, pelvic examination, and pregnancy testing for all reproductive-age women regardless of contraceptive use

Thats a significantly higher percentage than most other non-surgical weight loss treatments

Its important to consult with a healthcare provider to determine if Semaglutide is appropriate for your individual needs and health goals